论文部分内容阅读
目的探讨细胞角蛋白(CK)19作为循环肿瘤细胞的间接标志物的价值,以及CK19在肾癌患者外周血中的表达水平以及临床意义。方法选取健康人50名作为对照组,50例肾细胞癌患者作为肾癌组,首先进行对照组和肾癌组间CK19的指标测定,采用流式细胞术检测上述人群外周血中CK19的表达情况;再分析肾癌组内CK19的表达水平与肾癌病理分型、病理分期及组织学分级之间的关系。结果 50名对照组中无一例CK19阳性,50例肾癌组中24例CK19阳性;不同肾癌病理分型之间CK19表达差异无统计学意义(P>0.05),不同肾癌病理分期及组织学分级之间CK19表达差异具有统计学意义(P<0.05)。结论 CK19能够初步判断患者外周血循环肿瘤细胞的水平,对早期无创性诊断肾癌、预测其生物学行为有一定的参考价值,值得进一步探索和研究。
Objective To investigate the value of cytokeratin 19 as an indirect marker of circulating tumor cells and the expression of CK19 in peripheral blood of patients with renal cell carcinoma and its clinical significance. Methods Fifty healthy individuals were selected as the control group. Fifty patients with renal cell carcinoma were selected as the renal cell carcinoma group. The CK19 levels in the control group and the renal cell carcinoma group were measured. The expression of CK19 in the peripheral blood was detected by flow cytometry The relationship between the expression of CK19 and the pathological type, pathological stage and histological grade of renal cell carcinoma was analyzed again. Results CK19 was positive in none of the 50 control cases, and CK19 was positive in 24 cases of 50 cases of renal cell carcinoma. There was no significant difference in the expression of CK19 between different renal cell carcinoma (P> 0.05) There was a significant difference in the expression of CK19 between the two grades (P <0.05). Conclusions CK19 can initially determine the level of circulating tumor cells in patients with peripheral blood. It is valuable for the early diagnosis of noninvasive renal cell carcinoma and its biological behavior. It is worth further exploration and research.